Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article
NEUROLOGY 2004;63:1145
© 2004 American Academy of Neurology

October 12 Highlights and Commentary

Brain-penetrating ACE inhibitors and Alzheimer disease

Ohrui et al. found that brain-penetrating angiotensin-converting enzyme (ACE) inhibitors significantly slow the rate of cognitive decline in Alzheimer disease (AD) patients with hypertension compared with other antihypertensive drugs.

see page 1324

Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression: A handful of ACEs?

Commentary by David S. Knopman, MD

The Ohrui et al. clinical trial is based on the novel hypothesis that there is an alteration in ACE in AD. Drugs that inhibit ACE are readily available, including at least two, perindopril and captopril, that cross the blood–brain barrier. Ohrui et al. randomized 162 hypertensive mild to moderate AD patients to one of these two brain-penetrating ACE inhibitors (ACE-I), or a non-brain-penetrating ACE-I or calcium-channel blockers, and followed them for 1 year. The Mini-Mental State Examination was the sole outcome measure. Patients treated with the brain-penetrating ACE-Is did not decline while patients in the other two groups experienced large declines.

There are links between the treatment effect of brain-penetrating ACE-I and emerging evidence about microvascular mechanisms in AD1 as well as an overrepresentation of certain polymorphisms in the ACE gene in AD.2 The recently described reduction in dementia incidence with perindopril and indapamide in a large prospective study3 is also consistent with the findings here. This study’s findings are provocative and exciting, but readers must be skeptical. There are a number of methodologic weaknesses in the study. It is not clear whether perindopril, captopril, or both drove the effect. The amount of decline in the other two groups was much larger than expected. The lack of adverse events is surprising and the extremely high retention rate of patients in both arms of the study is unusual. Moreover, despite the randomization, the medications were not administered in a blinded fashion. At this point, the reviewers and editors concluded that this provocative work should be published. However, the findings with ACE-Is must be replicated in carefully controlled, randomized, blinded studies.

See page 1324

References

  1. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999; 13 suppl 3: S106–114.
  2. Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology. 2004; 62: 363–368.[Abstract/Free Full Text]
  3. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003; 163: 1069–1075.[Abstract/Free Full Text]

Related Article

Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression
T. Ohrui, N. Tomita, T. Sato-Nakagawa, T. Matsui, M. Maruyama, K. Niwa, H. Arai, and H. Sasaki
Neurology 2004 63: 1324-1325. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. L. Hemming and D. J. Selkoe
Amyloid {beta}-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor
J. Biol. Chem., November 11, 2005; 280(45): 37644 - 37650.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS